Reducing The Timeline By 30% To Produce A Monoclonal Cell Line Expressing A Clinical Candidate Bi-Specific Antibody

SystImmune is a biopharmaceutical company based near Seattle, Washington. It has its own antibody discovery platform, and the objective is to generate a single cell clone with maximal expression level of their candidate bispecific immune-oncology antibody, which is targeted to the treatment of solid tumour cancer. SystImmune decided to use the CHOZN (Sigma) cell line as their expression platform, and they also chose to adopt the minipool selection procedure for selection of higher producing clones.

SystImmune's chosen path forward to prove clonality was to introduce the Solentim Cell Metric CLD into their cell line development process. Using the Cell Metric, SystImmune will eliminate one round of limiting dilution in their CLD process which will save 6-8 weeks of work whilst still meeting the regulatory requirements.